Coherus BioSciences has completed the divestiture of its UDENYCA pegfilgrastim franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million, receiving $483.4 million upfront with potential for $75 million in milestone payments.
Coherus BioSciences' selective anti-CCR8 antibody CHS-114 demonstrated clinical efficacy in combination with toripalimab in head and neck squamous cell carcinoma, achieving a confirmed partial response in a heavily pretreated PD-1 refractory patient.
Coherus BioSciences presented final Phase 2 data for casdozokitug combined with atezolizumab and bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma.